Background. Vitamin D deficiency is found in the majority of patients with chronic kidney disease (CKD) and may contribute to various chronic diseases. Current guidelines suggest correcting reduced 25-hydroxyvitamin D [25(OH)D] concentrations in CKD patients with an estimated glomerular filtration rate (eGFR) <60 mL/min/ 1.73m 2 . Whether low 25(OH)D levels in these patients are associated with higher mortality is unclear. This issue was addressed in the present work. Methods. We examined 444 patients with eGFR <60 mL/ min/1.73m 2 from the Ludwigshafen Risk and Cardiovascular Health Study. This prospective cohort study includes Caucasian patients without primary kidney disease who were routinely referred to coronary angiography at baseline (1997)(1998)(1999)(2000). Conclusions. Low 25(OH)D levels are associated with increased all-cause and cardiovascular mortality in CKD patients. These findings support suggestions to correct vitamin D deficiency, but whether vitamin D supplementation improves survival remains to be proven in randomized controlled trials.
Introduction
A poor vitamin D status, classified according to reduced 25-hydroxyvitamin D [25(OH)D] levels, is present in the majority of patients with chronic kidney disease (CKD) [1] . Impaired vitamin D metabolism in CKD including reduced vitamin D synthesis in the skin and urinary loss of vitamin D metabolites contribute to such a high prevalence of vitamin D deficiency [2, 3] . This is of particular concern because accumulating evidence suggests that vitamin D deficiency itself may exert adverse consequences on renal structure and function [3] [4] [5] [6] . Furthermore, beyond its classic associations with CKD-mineral and bone disorders (CKD-MBD), vitamin D deficiency has also been linked to increased cardio-and cerebrovascular risk, cancer, autoimmune and infectious diseases [6] [7] [8] [9] [10] [11] [12] [13] [14] . Considering the proposed health benefits of vitamin D, the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines suggest that it is reasonable to correct low 25(OH)D concentrations with natural vitamin D in CKD patients Stages 3-5 [15] . Natural vitamin D supplementation in CKD patients has been shown to improve some surrogate parameters of cardiovascular risk and CKD-MBD including suppression of parathyroid hormone (PTH) levels [16] [17] [18] [19] [20] . There are, however, no data from randomized controlled trials (RCTs) among CKD patients on outcomes such as mortality. Observational studies which addressed the association of 25(OH)D and mortality among CKD patients not on dialysis are sparse and yielded inconsistent results [21] [22] [23] . It is therefore of considerable interest to clarify whether low 25(OH)D levels predict adverse outcomes in such cohorts. We therefore investigated CKD patients with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m 2 derived from the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study, a cohort of patient referred to coronary angiography and without primary kidney disease. Low 25(OH)D levels have been previously associated with adverse outcomes in the entire LURIC cohort [24] [25] [26] . The current work is, however, restricted to dialysis-free CKD patients with a significantly longer follow-up than in previous publications of that study. Our main aim was to evaluate whether 25(OH)D levels are associated with all-cause and cardiovascular mortality.
Materials and methods

Study population
The LURIC Study is a prospective cohort study of patients referred to coronary angiography and without primary kidney disease [27] . This study was designed to identify genetic and environmental risk factors for cardiovascular diseases [27] . Detailed descriptions of the baseline examinations and follow-up procedures have been published previously [24] [25] [26] [27] . In brief, baseline examinations were performed between June 1997 and January 2000 at a tertiary care centre in Southwest Germany (49°29 min north latitude). The entire study population consists of 3316 Caucasian patients who were routinely referred to coronary angiography. Coronary angiography was commonly indicated because of clinical symptoms (i.e. chest pain) or results of noninvasive tests that suggested myocardial ischaemia. Exclusion criteria were any acute illness other than acute coronary syndrome, any predominant noncardiac disease and a history of malignancy within 5 years prior to study inclusion. All study participants gave written informed consent and ethical approval was obtained from the 'Ä rztekammer Rheinland-Pfalz'. Coronary artery disease (CAD) was defined as a stenosis of !50% in at least one of 15 coronary segments [27] . Season was categorized into a binary variable (summer season: May-October and winter season: November-April).
Laboratory methods
Routine laboratory methods have been previously described in detail [27] . Venous blood samples were drawn in the morning before coronary angiography. All standard laboratory parameters including 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] were determined on a daily or weekly basis at baseline, whereas remaining blood samples were snap frozen for determinations of further parameters and stored at À80°C until analysis [27] .
Measurements of 25(OH)D serum concentrations were performed by radioimmunoassay (RIA) (DiaSorin, Antony, France; Stillwater, OK) with an intra-and inter-assay coefficient of variation (CV) of 8.6 and 9.2%, respectively. We validated this method by measuring 25(OH)D levels in 100 randomly chosen samples with liquid chromatography tandem mass spectrometry with isotopic-labeled internal standard and two fragments m/z 401.4/382.2 (quantifier) and 401.4/365.3 (qualifier). Serum levels of 25(OH)D obtained by RIA and liquid chromatography tandem mass spectrometry were highly significantly correlated (r ¼ 0.875; P ¼ 0.001). Serum concentrations of 1,25(OH)2D were also determined by RIA (Nichols Institute Diagnostika GmbH, Bad Nauheim, Germany) on a multicrystal counter (Berthold LB2014; DiaSorin SA). Serum Intact PTH was measured in serum by ElectroChemiLuminescence Immunoassay on an Elecsys 2010 (Roche Diagnostics, Mannheim, Germany). The normal range for this assay is 15-65 pg/mL and the inter-assay CV is 5.7-6.3%. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) was determined by ElectroChemiLuminescence on an Elecsys 2010 (Roche Diagnostics). C-reactive protein was measured by immunonephelometry (N High Sensitivity CRP; Dade Behring, Marburg, Germany). Plasma aldosterone was determined by RIA (Active aldosterone; Diagnostic Systems Laboratories, Sinsheim, Germany) and plasma renin concentration by an immunoradiometric assay (Active Renin; Nichols Institute Diagnostics, San Juan, Capistrano, CA). eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [28] . Classification of diabetes mellitus was done according to the American Diabetes Association including the new criterion of glycosylated haemoglobin A1c (HbA1c) ! 6.5% [29] .
Follow-up procedures
Detailed follow-up procedures have been published previously [24] [25] [26] [27] . In brief, information on vital status was obtained from person registries.
Classification of the causes of death was done by reviewing death certificates, medical records from hospitals and autopsy data. Three experienced clinicians, who were blinded to any other data, except the above described information for the assignment of the causes of death, performed the classification of cause-specific mortality. In the case of disagreement concerning the classification, it was discussed and the final decision was made by one of the principle investigators of the LURIC Study. Cardiovascular deaths included sudden cardiac death (SCD), death due to heart failure, fatal myocardial infarction (MI), death after interventions to treat CAD, death due to other cardiac causes and fatal strokes.
Statistical analyses
All patients from the LURIC cohort with an eGFR <60 mL/min/1.73m 2 and available 25(OH)D concentrations were included into the present analyses. These patients were stratified according to their 25(OH)D levels. In line with widely used cutoff values for 25(OH)D status, we formed four groups: severely vitamin D deficient, <10 ng/mL; moderately vitamin D deficient, 10 to <20 ng/mL; vitamin D insufficient, 20 to <30 ng/mL and vitamin D sufficient, !30 ng/mL. All skewed continuous parameters were logarithmically transformed (log10) before use in parametric analyses. Categorical data are presented as proportions and continuous variables as means AE SDs (normally distributed variables) or as medians with interquartile range (skewed variables). Group comparisons were performed by analysis of variance with P for trend for continuous parameters and by chi-square test with P for linear-by-linear test for categorical variables. Fisher's exact test was used in case of groups with counts of <5.
Differences in all-cause and cardiovascular mortality between the vitamin D groups were graphically displayed by Kaplan-Meier curves followed by log-rank tests. Cox proportional hazard ratios (HRs) with 95% confidence intervals (CIs) for all-cause and cardiovascular mortality were calculated for the different vitamin D groups by using vitamin D-sufficient patients as the reference. In addition, we calculated HR per increases of 10 ng/mL in 25(OH)D levels. We performed crude (unadjusted) models and multivariable adjusted models as indicated including adjustments for age and sex (Model 1), additional adjustments for risk factors for mortality and cardiovascular diseases as well as season (Model 2) and additional adjustments for parameters of mineral metabolism (Model 3). Furthermore, we tested for interactions with sex, CKD stage (CKD Stage 3, yes/no) and PTH levels by adding product terms of 25(OH)D with either sex, CKD stage or PTH to our multivariable adjusted Cox proportional hazard models. Additionally, we calculated HR for all-cause and cardiovascular mortality according to 25(OH)D as well as 1,25(OH)2D quartiles derived from the values of all 444 CKD patients. All statistical tests were two sided and a P-value <0.05 was considered statistically significant. Data were analysed using SPSS 17.0 statistical package (SPSS Inc., Chicago, IL).
Results
From the entire LURIC cohort of 3316 study participants, 448 showed an eGFR <60 mL/min/ 2 ) and 9 with CKD Stage 5 (eGFR < 15 mL/min/1.73m 2 ; no patient on dialysis). Only 10 patients reported on vitamin D supplement intake and their 25(OH)D levels were not significantly different from the remaining study cohort. Baseline clinical and laboratory characteristics according to vitamin D status of the 444 patients included into the present work are shown in Table 1 . Groups with lower 25(OH)D levels showed an increased cardiovascular risk profile as well as disturbances in mineral metabolism including elevated PTH and reduced 1,25(OH)2D levels (for details, see Table 1 ). The 25(OH)D concentrations (mean AE SD) were significantly higher in summer (17.8 AE 10.3 ng/mL) compared to winter season (12.4 AE 6.7 ng/mL; P < 0.001).
During a median follow-up time of 9.4 years, 227 patients died including 159 deaths due to cardiovascular causes (67 SCD, 22 fatal MI, 41 heart failure deaths, 6 deaths after interventions to treat CAD, 8 deaths due to other cardiac causes and 15 fatal strokes). No patients were lost during follow-up but in four deceased patients, the available information was not sufficient to classify their causes of death. These patients were included into the analyses of all-cause mortality but were excluded for the analyses of cardiovascular mortality.
Kaplan-Meier curves followed by log-rank tests showed significantly increased risk of all-cause and cardiovascular mortality in groups with lower 25(OH)D concentrations (log-rank test: P < 0.001 for both; see Figure 1a and b).
Risk of all-cause mortality was significantly increased in severely vitamin D-deficient patients when compared to the vitamin D-sufficient group: HR (95% CI) of 4.38 (2.13-9.00). This HR remained significant even after multivariable adjustments (see Table 2 ). For cardiovascular mortality, the respective unadjusted and fully adjusted HRs in the severely vitamin D deficient group were 6.07 (2.22-16.6) and 5.61 (1.89-16.6), respectively. Additional adjustments of the multivariate models (Model 3 in Table 2 ) for either drugs (ACE-inhibitors, beta-blockers, aspirin/platelet agents, statins and diuretics), components of the reninangiotensin system (aldosterone and renin), albumin or any other parameter of Table 1 did not materially alter the association of vitamin D status with all-cause or cardiovascular mortality (data not shown). Glucocorticoid treatment and estrogen hormonal replacement therapy were prevalent in 2.9 and 2.0% of our study participants, respectively. Exclusion of these latter patients did also not materially alter our findings. Furthermore, use of previous definitions for diabetes mellitus (WHO 1999 criteria) or use 
Discussion
This study among CKD patients Stages 3-5 not on dialysis shows that low 25(OH)D levels are associated with an increased risk of all-cause and cardiovascular mortality. These results remained significant even after multivariable adjustments and were not significantly modified by PTH levels.
Our results add significantly to the current knowledge on the association of 25(OH)D levels and mortality in CKD [21] [22] [23] [30] [31] [32] [33] [34] [35] [36] . Increased mortality in vitamin D-deficient patients has been reported in most but not all studies in this field [21] [22] [23] [30] [31] [32] [33] [34] [35] [36] . Previous studies have largely included dialysis patients and/or CKD patients with an eGFR !60 mL/min/1.73m 2 . We are, to the best of our knowledge, the first to show that low 25(OH)D concentrations are significantly associated with total mortality in CKD patients Stages 3-5 not on dialysis. This is of particular importance because the 2009 KDIGO guidelines suggest that it is reasonable to correct reduced 25(OH)D levels in CKD patients with a GFR <60 mL/min/1.73m 2 [15] . Hence, our observational data are in line with this recommendation, although we are well aware that we cannot draw conclusions regarding causality from our prospective follow-up study.
Another important result of our work is the missing interaction with PTH concentrations. This indicates that the association of 25(OH)D status and mortality is not significantly modified by PTH levels. In a previous study among 168 non-dialysis patients, there was also no respective effect modification by PTH status [21] . In this context, it should be stressed that in the 2009 KDIGO guidelines, one recommendation to measure 25(OH)D levels in CKD is restricted to patients with elevated PTH concentrations [15] . Our findings, however, suggest that determinations of vitamin D status may be useful for risk stratification regardless of prevailing PTH status. We have to acknowledge that elevations of PTH concentrations are indeed an adverse consequence of vitamin D deficiency-related disturbances in mineral metabolism and are itself associated with increased all-cause and cardiovascular mortality [37] . There exists, however, accumulating evidence that beyond secondary hyperparathyroidism low 25(OH)D levels exert deleterious consequences, which are also mediated by PTH-independent pathways [14] . This notion is supported by the fact that vitamin D metabolites regulate~3% of the human genome including various genes with relevance for potentially life threatening diseases such as cardiovascular (e.g. renin suppression), malignant or infectious diseases [6] [7] [8] [9] [10] [11] [12] [13] [14] . Toward this, our data support a particularly strong association of vitamin D deficiency with increased cardiovascular risk. We did not, however, find significant associations of vitamin D status with CAD suggesting that other pathways than coronary atherosclerosis may underlie our results. Proposed mechanisms include direct beneficial effects on myocardial structure and function as well as antihypertensive, antidiabetic and anti-inflammatory properties of vitamin D [6-14, 38, 39] . It should also be pointed out that in CKD patients, a sufficient vitamin D status may protect against further decline of renal function and various studies suggest antiproteinuric effects of vitamin D metabolites [3] [4] [5] [6] 38] . The vitamin D-insufficient group yielded a nonsignificant trend toward an increased risk of cardiovascular mortality. This may suggest that in terms of cardiovascular diseases, the risk for adverse outcomes might hypothetically increase at the vitamin D-insufficient stage and not only at 25(OH)D levels <20 ng/mL, as it seems to apply for all-cause mortality (see Table 2 ).
In contrast to the compelling evidence from observational studies on the associations of low 25(OH)D levels with adverse outcomes, only few RCT are available with natural vitamin D supplementation in CKD patients [17] [18] [19] [20] . These trials have shown that natural vitamin D therapy improves surrogate parameters for cardiovascular risk and CKD-MBD including decreases in PTH levels and increases in 1,25(OH)2D [17] [18] [19] [20] . No previous RCT has, however, addressed the effect of vitamin D supplementation on mortality in CKD. In this context, a meta-analysis of RCTs comprising frail elderly patients demonstrated that vitamin D supplementation is associated with significantly reduced mortality risk [40] . Among CKD patients, active vitamin D treatment with 1,25(OH)2D or its analogues (i.e. paricalcitol) seems to reduce mortality but this is not the adequate therapy to correct vitamin D deficiency (reduced 25(OH)D concentrations) which can be treated with natural vitamin D supplementation [41] . According to a widely accepted simplified concept, the conversion of 25(OH)D to 1,25(OH)2D by 1-alpha hydroxylase seems to determine tissue levels of 1,25(OH)2D in various organs with significant activities of this enzyme [14, 42] . By contrast, circulating 1,25(OH)2D serum levels are of particular importance for vitamin D receptor (VDR) activation in those cells with low or missing 1-alpha hydroxylase activity [14, 42] . Hence, an intriguing hypothesis is that natural and active vitamin D treatment have the same target receptor (VDR), but depending on local 1-alpha hydroxylase activities, certain tissues might be more sensitive to either 1,25(OH)2D or 25(OH)D. In the LURIC Study, mortality prediction was stronger for low 25(OH)D compared to low 1,25(OH)2D concentrations. This underlines the clinical relevance of 25(OH)D levels, which circulate in up to 1000-fold higher concentrations compared to 1,25(OH)2D. Of note is that natural vitamin D therapy is much cheaper and safer than active vitamin D treatment and is also suggested to be useful for the treatment of various chronic diseases [43, 44] . Sun exposure can also effectively increase 25(OH)D levels by ultraviolet-B-induced vitamin D synthesis in the skin but possible side effects such as skin cancer have to be considered [6, 43, 44] .
It should also be discussed that low 25(OH)D levels might be simply the consequence of underlying diseases or high risk conditions which cause vitamin D deficiency due to, e.g., morbidity associated reduced sunlight exposure or low vitamin D intake. We aimed to address this issue by adjusting for various parameters that might themselves contribute to a poor vitamin D status.
Nevertheless, our results are clearly limited due to the observational design of our study, which precludes conclusions regarding causality. Furthermore, we investigated a specific study population, namely Caucasian CKD patients referred to coronary angiography. Hence, this limits the generalizability of our results to other CKD cohorts. Due to missing urine measurements, we were not able to adjust our prospective analyses for the degree of albuminuria, which is a limitation of our work. In this context, we also want to point out that when considering promising data on proposed antiproteinuric effects of vitamin D [3, 38] , albuminuria can be rather regarded as a parameter of the causal pathway than as a confounder for the association of vitamin D deficiency and (cardiovascular) mortality. Furthermore, our prospective analyses were adjusted for a panel of possible confounders but we cannot rule out the existence of residual confounding. On the other hand, we might have overadjusted our statistical analyses with parameters of the causal pathway of vitamin D deficiency. Our data are also limited by the fact that clinical and biochemical measurements were only performed once at baseline, which precludes considerations of time-dependent changes of these parameters during follow-up.
In conclusion, we have shown in a cohort of CKD patients Stages 3-5 that low 25(OH)D levels predict an increased risk of all-cause and cardiovascular mortality. There was no significant interaction with PTH concentrations suggesting that regardless of the prevailing PTH status measurements of 25(OH)D might be useful for risk stratification in virtually all patients with an eGFR <60 mL/min/1.73m 2 . These observational data support the 2009 KDIGO guidelines concerning the recommendation to correct reduced 25(OH)D levels in CKD patients. Whether natural vitamin D supplementation in CKD patients improves survival remains to be proven in RCT.
